Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
https://doi.org/10.21256/zhaw-25991| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study |
| Autor/-in: | Riesterer, Oliver Ademaj, Adela Puric, Emsad Eberle, Brigitte Beck, Marcus Gomez, Silvia Marder, Dietmar Oberacker, Eva Rogers, Susanne Hälg, Roger A. Kern, Thomas Schwenne, Sonja Stein, Jürgen Stutz, Emanuel Timm, Olaf Zschaeck, Sebastian Weyland, Mathias S. Veltsista, Paraskevi D. Wyler, Stephen Wust, Peter Scheidegger, Stephan Bodis, Stephan Ghadjar, Pirus |
| et. al: | No |
| DOI: | 10.1080/02656736.2022.2109763 10.21256/zhaw-25991 |
| Erschienen in: | International Journal of Hyperthermia |
| Band(Heft): | 39 |
| Heft: | 1 |
| Seite(n): | 1078 |
| Seiten bis: | 1087 |
| Erscheinungsdatum: | 2022 |
| Verlag / Hrsg. Institution: | Taylor & Francis |
| ISSN: | 0265-6736 1464-5157 |
| Sprache: | Englisch |
| Schlagwörter: | Bladder cancer; Bladder preservation; Radiochemotherapy; Regional hyperthermia; Tetramodal therapy; Aged; Combined modality therapy; Human; Muscle; Quality of life; Hyperthermia, induced; Urinary bladder neoplasm |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik 616: Innere Medizin und Krankheiten |
| Zusammenfassung: | Background: Transurethral resection of bladder tumor (TUR-BT) followed by chemoradiation (CRT) is a valid treatment option for patients with muscle-invasive bladder cancer (MIBC). This study aimed to investigate the efficacy of a tetramodal approach with additional regional hyperthermia (RHT). Methods: Patients with stages T2–4 MIBC were recruited at two institutions. Treatment consisted of TURBT followed by radiotherapy at doses of 57–58.2 Gy with concurrent weekly platinum-based chemotherapy and weekly deep RHT (41–43 C, 60 min) within two hours of radiotherapy. The primary endpoint was a complete response six weeks after the end of treatment. Further endpoints were cystectomy-free rate, progression-free survival (PFS), local recurrence-free survival (LRFS), overall survival (OS) and toxicity. Quality of life (QoL) was assessed at follow-up using the EORTC-QLQ-C30 and QLQ-BM30 questionnaires. Due to slow accrual, an interim analysis was performed after the first stage of the two-stage design. Results: Altogether 27 patients were included in the first stage, of these 21 patients with a median age of 73 years were assessable. The complete response rate of evaluable patients six weeks after therapy was 93%. The 2-year cystectomy-free rate, PFS, LRFS and OS rates were 95%, 76%, 81% and 86%, respectively. Tetramodal treatment was well tolerated with acute and late G3–4 toxicities of 10% and 13%, respectively, and a tendency to improve symptom-related quality of life (QoL) one year after therapy. Conclusion: Tetramodal therapy of T2–T4 MIBC is promising with excellent local response, moderate toxicity and good QoL. This study deserves continuation into the second stage. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/25991 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | CC BY 4.0: Namensnennung 4.0 International |
| Departement: | School of Engineering |
| Organisationseinheit: | Institut für Angewandte Mathematik und Physik (IAMP) |
| Enthalten in den Sammlungen: | Publikationen School of Engineering |
Dateien zu dieser Ressource:
| Datei | Beschreibung | Größe | Format | |
|---|---|---|---|---|
| 2022_Riesterer-etal_Tetramodal-therapy-with-transurethral-resection-bladder-cancer.pdf | 1.56 MB | Adobe PDF |  Öffnen/Anzeigen |
Zur Langanzeige
Riesterer, O., Ademaj, A., Puric, E., Eberle, B., Beck, M., Gomez, S., Marder, D., Oberacker, E., Rogers, S., Hälg, R. A., Kern, T., Schwenne, S., Stein, J., Stutz, E., Timm, O., Zschaeck, S., Weyland, M. S., Veltsista, P. D., Wyler, S., et al. (2022). Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study. International Journal of Hyperthermia, 39(1), 1078–1087. https://doi.org/10.1080/02656736.2022.2109763
Riesterer, O. et al. (2022) ‘Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study’, International Journal of Hyperthermia, 39(1), pp. 1078–1087. Available at: https://doi.org/10.1080/02656736.2022.2109763.
O. Riesterer et al., “Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study,” International Journal of Hyperthermia, vol. 39, no. 1, pp. 1078–1087, 2022, doi: 10.1080/02656736.2022.2109763.
RIESTERER, Oliver, Adela ADEMAJ, Emsad PURIC, Brigitte EBERLE, Marcus BECK, Silvia GOMEZ, Dietmar MARDER, Eva OBERACKER, Susanne ROGERS, Roger A. HÄLG, Thomas KERN, Sonja SCHWENNE, Jürgen STEIN, Emanuel STUTZ, Olaf TIMM, Sebastian ZSCHAECK, Mathias S. WEYLAND, Paraskevi D. VELTSISTA, Stephen WYLER, Peter WUST, Stephan SCHEIDEGGER, Stephan BODIS und Pirus GHADJAR, 2022. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study. International Journal of Hyperthermia. 2022. Bd. 39, Nr. 1, S. 1078–1087. DOI 10.1080/02656736.2022.2109763
Riesterer, Oliver, Adela Ademaj, Emsad Puric, Brigitte Eberle, Marcus Beck, Silvia Gomez, Dietmar Marder, et al. 2022. “Tetramodal Therapy with Transurethral Resection Followed by Chemoradiation in Combination with Hyperthermia for Muscle-Invasive Bladder Cancer : Early Results of a Multicenter Phase IIB Study.” International Journal of Hyperthermia 39 (1): 1078–87. https://doi.org/10.1080/02656736.2022.2109763.
Riesterer, Oliver, et al. “Tetramodal Therapy with Transurethral Resection Followed by Chemoradiation in Combination with Hyperthermia for Muscle-Invasive Bladder Cancer : Early Results of a Multicenter Phase IIB Study.” International Journal of Hyperthermia, vol. 39, no. 1, 2022, pp. 1078–87, https://doi.org/10.1080/02656736.2022.2109763.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.